Last reviewed 2026-05-22 · How we verify

Dibazol (BENDAZOL)

Phase 2 active Small molecule ✓ Verified May 2026

Dibazol (generic name: BENDAZOL) is a bendazol drug. It is currently in Phase 2 development for Hypertensive disorder.

Dibazol works by interacting with a specific biological target to produce a therapeutic effect.

Dibazol is a small molecule with the synonyms BENDAZOL and NSC-60020. Its exact mechanism and clinical uses are not specified in the provided information.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BENDAZOL
Drug class	bendazol
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Unfortunately, the exact way Dibazol works is not well understood, but it is thought to affect the body's blood pressure regulation system. This may involve influencing the activity of certain cells or chemicals in the body that help control blood pressure. By doing so, Dibazol may help to lower blood pressure and alleviate symptoms of hypertensive disorders.

Approved indications

Hypertensive disorder

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dibazol CI brief — competitive landscape report
Dibazol updates RSS · CI watch RSS

Frequently asked questions about Dibazol

What is Dibazol?

Dibazol (BENDAZOL) is a bendazol drug, indicated for Hypertensive disorder.

How does Dibazol work?

Dibazol works by interacting with a specific biological target to produce a therapeutic effect.

What is Dibazol used for?

Dibazol is indicated for Hypertensive disorder.

What is the generic name of Dibazol?

BENDAZOL is the generic (nonproprietary) name of Dibazol.

What drug class is Dibazol in?

Dibazol belongs to the bendazol class. See all bendazol drugs at /class/bendazol.

What development phase is Dibazol in?

Dibazol is in Phase 2.

Drug class: All bendazol drugs
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypertensive disorder

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing